SLC22A1 Variant (Pro341Leu) Test

Your liver acts as the body's primary processing center for medications. Before most drugs can do their job, they need to get inside liver cells. A single protein, called organic cation transporter 1, or OCT1, sits on the surface of liver cells and functions like a gate, pulling medications and natural compounds from your bloodstream into the liver. If your version of this gate does not open as wide as expected, medications may linger in your blood longer, reach your liver less efficiently, or produce side effects at standard doses.

The SLC22A1 c.1022C>T variant (also known as p.Pro341Leu or P341L) is a single letter change in the DNA of the SLC22A1 gene, which provides the blueprint for OCT1. This change swaps one amino acid (a building block of proteins), proline, for another, leucine, at position 341 of the protein. The result: your OCT1 transporter still makes it to the cell surface and still works, but laboratory tests using a reference compound (tetraethylammonium, or TEA) showed transport at roughly 65% of normal capacity. The actual impact varies by substrate (the specific molecule being transported): some drugs are affected more than others, and a few may not be affected at all. That partial reduction may not matter for everyday health, but it can meaningfully change how your body handles certain drugs.

What This Variant Does to Drug Transport

OCT1 is not a single-purpose transporter. It moves a wide range of positively charged molecules across cell membranes without requiring energy, acting as a two-way gate that lets molecules pass along their natural concentration gradient without requiring energy (a process called facilitated diffusion). The Pro341Leu substitution does not break this gate or prevent it from reaching its proper location on the liver cell membrane. Instead, it slows throughput. Laboratory studies using human kidney cells (HEK293) and frog egg cells (Xenopus oocytes) confirmed that the variant protein sits in the right place but moves test substances at a reduced rate.

This matters because OCT1 handles the first step for many drugs: getting them from the blood into liver cells. When that step is slower, medications that depend on liver processing may behave differently. You could end up with higher drug concentrations in your blood (since less drug enters the liver), a larger area under the curve (a measure of total drug exposure over time), or a reduced volume of distribution (meaning the drug stays more concentrated in the bloodstream rather than spreading into tissues).

Metformin Response

The most studied clinical consequence of SLC22A1 variants involves metformin, the most widely prescribed medication for type 2 diabetes. Metformin works primarily inside liver cells, where it reduces glucose production. If OCT1 is not efficiently pulling metformin into those cells, the drug may not reach therapeutic concentrations at its target, even when blood levels look adequate. However, the relationship between the Pro341Leu variant and metformin transport specifically is more nuanced than for other OCT1 variants. Early laboratory cell-culture studies found that Pro341Leu did not reduce metformin uptake in the way it reduced transport of other test compounds, though some pharmacokinetic studies in Korean populations found that Pro341Leu carriers had altered metformin blood concentration profiles. Other well-studied OCT1 variants (such as R61C, M420del, and G465R) have stronger and more consistent evidence of reducing metformin transport and clinical response.

A systematic review of studies on SLC22A1 gene variations and metformin found that certain variants alter both the drug's blood concentration profile and its ability to lower HbA1c (the three-month average blood sugar marker). Some studies reported two to three-fold differences in treatment response rates between patients with different SLC22A1 genotypes. Research in Mexican, Indian, Indonesian, and Lebanese populations has confirmed that these associations appear across ethnic groups, though the specific variants involved and their frequencies differ. Most of this evidence comes from variants other than Pro341Leu (such as R61C, M420del, and rs628031), so the degree to which Pro341Leu alone alters metformin response remains less certain.

If you carry the Pro341Leu variant and take metformin, this does not automatically mean the drug will fail. The evidence linking this specific variant to reduced metformin response is less consistent than for other OCT1 variants like R61C or M420del. However, if you also carry additional reduced-function SLC22A1 variants, their combined effect could be more meaningful. If your blood sugar control seems stubbornly resistant to metformin despite good adherence, your overall SLC22A1 genotype could be part of the explanation. Knowing your genotype gives you and your prescriber a concrete piece of the puzzle rather than defaulting to dose escalation or adding second agents without understanding why the first one underperformed.

Cancer Treatment Implications

OCT1 has also been proposed as a transporter for imatinib, a targeted therapy for chronic myeloid leukemia (CML). Some clinical studies have found that SLC22A1 variants, including splice variants that disrupt the protein, are associated with delayed molecular responses in CML patients on imatinib. However, whether OCT1 actually transports imatinib into leukemic cells is debated. A 2014 study using multiple experimental approaches, including OCT1-knockout mice, found that cellular imatinib uptake was independent of OCT1, and that leukemic cells did not express OCT1 protein. Other research groups have reported clinical correlations between OCT1 activity measurements and imatinib response. The evidence remains conflicting, and the role of OCT1 genetic variants in imatinib response is not as straightforward as initially proposed.

Other OCT1 substrate drugs span a wide range, including certain pain medications (morphine, tramadol), antiemetics used during chemotherapy (ondansetron, tropisetron), and some antiviral and anticancer agents (oxaliplatin, lamivudine). For each of these, reduced OCT1 function could alter how much active drug reaches the tissue where it needs to work.

Beyond Drugs: Metabolic Roles

OCT1 does not just move drugs. It also transports several compounds your body makes and needs, including thiamine (vitamin B1), the building blocks of certain brain chemicals (serotonin, dopamine, norepinephrine), and acylcarnitines (molecules involved in burning fat for energy inside your cells' energy-producing compartments, the mitochondria). Large-scale genetic studies have linked SLC22A1 variants to blood levels of acylcarnitines, and OCT1 appears to control their movement out of the liver and into circulation.

OCT1 is also a high-capacity thiamine transporter, and research shows that OCT1 function affects how much thiamine the liver stores. Since thiamine is essential for energy metabolism throughout the body, and since metformin itself interacts with thiamine transport through OCT1, the intersection of this variant with metformin use creates a layered pharmacological picture that extends beyond glucose control alone.

Population Frequency and Ethnic Variation

How common this variant is depends heavily on ancestry. The Pro341Leu change was first identified in Japanese populations at a frequency of about 16.8%. Global analyses of OCT1 loss-of-function variants reveal dramatic variation: roughly 9% of people of European descent completely lack or have very low OCT1 activity (carrying zero fully active OCT1 alleles), while up to 80% of native South American Indian populations lack fully functional OCT1. Most East Asian and Oceanian populations retain functional OCT1, with evidence that evolutionary pressure has favored keeping this transporter working well in these groups.

This ethnic variation matters for two reasons. First, the clinical impact of any single variant depends on what other SLC22A1 variants you carry. OCT1 function reflects the combined effect of potentially multiple changes across both copies of your gene. Second, studies conducted in one population may not directly apply to another. A variant that is common in Japanese populations and rare in European populations will have different research depth in each group.

How This Differs From Standard Pharmacogenetic Panels

Standard pharmacogenetic panels typically test 12 genes, including well-known drug metabolism enzymes like CYP2D6 and CYP2C19. SLC22A1 is not included on most of these panels. A "normal" result on a standard pharmacogenetic test does not mean your OCT1 transporter is working at full capacity. It means OCT1 was never evaluated. The International Transporter Consortium has recommended that SLC22A1 variants be considered during drug development, but routine clinical testing has not caught up.

The classification system used for most genetic variants (the ACMG/AMP framework) was designed for disease-causing mutations, not pharmacogenetic variants (genetic changes that affect drug response rather than causing disease on their own). Pharmacogenetic findings like Pro341Leu are instead interpreted using the Clinical Pharmacogenetics Implementation Consortium (CPIC) framework, which focuses on how a variant changes drug response rather than whether it causes a disease.

Reference Ranges

Because this is a genetic variant rather than a measurable blood level, there are no concentration-based reference ranges, optimal levels, or clinical cutpoints. You either carry this variant or you do not. The test result is qualitative: it reports your genotype (the specific DNA letters at this position on both copies of your SLC22A1 gene).

The functional impact also depends on whether you carry additional SLC22A1 variants on the same or opposite gene copy. Variants like M420del, R61C, and G401S can have additive effects, meaning the total picture of your OCT1 function comes from all variants combined, not just this one.

Why You Only Need to Test Once

Unlike blood biomarkers that fluctuate with diet, exercise, sleep, and stress, a genetic variant is fixed at conception. Your SLC22A1 genotype will not change over your lifetime. You only need to be tested once. There is no biological variability, no diurnal rhythm, and no need for fasting or sample timing. A single result is definitive.

That said, what makes this result most useful is context. Knowing your Pro341Leu status before you start metformin, imatinib, or another OCT1 substrate drug means your prescriber can anticipate whether standard dosing is likely to produce the expected response, or whether closer monitoring and earlier dose adjustments are warranted. The value of this test grows every time you start a new OCT1 substrate medication throughout your life.

Drug Interactions That Layer on Top

Even people with fully functional OCT1 can experience reduced transporter activity if they take medications that block OCT1. Known inhibitors include verapamil (a blood pressure and heart rhythm medication), quinidine (an anti-arrhythmic), and spironolactone (a diuretic). If you already carry the Pro341Leu variant and then take one of these inhibitors, the combined effect could reduce your effective OCT1 function well below the already-reduced baseline this variant produces.

Conversely, if you already have reduced OCT1 function from this variant, adding an OCT1 inhibitor may have less additional impact than it would in someone with wild-type OCT1, because there is less functional transporter left to block. This creates a genotype-dependent drug interaction profile that standard interaction databases do not account for.

Liver Disease and OCT1 Expression

OCT1 expression in the liver is not fixed even among people with the same genotype. Research has shown that cholestasis (a condition where bile flow from the liver is impaired) significantly reduces OCT1 protein levels in liver cells. This means that someone with an already reduced-function variant who develops liver disease could experience a further decline in drug transport capacity, compounding the pharmacogenetic effect.